Overview
Babesiosis, particularly caused by Babesia divergens, is a tick-borne disease primarily affecting cattle but with potential zoonotic transmission to humans, especially those with compromised immune systems such as splenectomized individuals 12. This condition leads to significant economic impacts due to morbidity in livestock characterized by fever, anemia, hemoglobinuria, and reduced productivity 3. While rare in Norway, the disease underscores the importance of vigilant surveillance and diagnostic capabilities in regions where tick populations and tick-borne pathogens are prevalent, ensuring timely intervention and control measures 4. Understanding and monitoring Babesia divergens infections are crucial for safeguarding both animal and public health in endemic areas 5. 1 Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. 2 The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania. 3 Development of a capture sequencing assay for enhanced detection and genotyping of tick-borne pathogens. 4 Research progress on diagnostic techniques for different Babesia species in persistent infections. 5 Human Babesia odocoilei and Bartonella spp. co-infections in the Americas.Pathophysiology Babesia divergens infection primarily targets erythrocytes, leading to a cascade of pathophysiological events that can result in significant clinical manifestations, particularly in immunocompromised hosts or individuals with underlying conditions like sickle cell anemia 5. Upon invasion, Babesia divergens replicates within the host erythrocytes, disrupting normal red blood cell (RBC) function and integrity. The parasite's intracellular development triggers host immune responses, including the activation of innate and adaptive immunity mechanisms, which can lead to increased RBC destruction through mechanisms such as intravascular hemolysis 1. This destruction results in hemolytic anemia, characterized by anemia, hemoglobinuria, and potentially severe complications like acute kidney injury due to hemoglobinuria-induced tubular damage 2. The presence of Babesia divergens within erythrocytes also modulates the host cell's cytoskeleton and membrane integrity, contributing to morphological changes that can exacerbate conditions like sickle cell anemia 5. In individuals with sickle cell anemia, the already compromised RBC structure becomes further destabilized, potentially accelerating sickling episodes and increasing microvascular obstruction 3. This interaction between Babesia divergens and sickle cell pathology can exacerbate hemolytic anemia, leading to more pronounced clinical symptoms such as fever, fatigue, and severe anemia 4. Additionally, the chronic inflammatory response triggered by the parasite can contribute to systemic effects, including thrombocytopenia and disseminated intravascular coagulation (DIC), further complicating clinical management 6. Immune evasion strategies employed by Babesia divergens, such as antigenic variation and modulation of host cell signaling pathways, enable prolonged parasitemia and persistent infection 7. These mechanisms interfere with the host's ability to mount an effective immune response, allowing for continuous parasite replication and RBC damage over time. Consequently, patients may experience recurrent episodes of fever and hemolytic crises, underscoring the importance of early diagnosis and targeted therapeutic interventions to mitigate these pathophysiological processes 8. Effective management often involves antimonial compounds like diminazene aceturate, which can target the parasite while minimizing adverse effects on host RBCs . However, treatment strategies must be carefully tailored to individual patient conditions to address both the parasitic infection and underlying host vulnerabilities effectively.
Epidemiology Babesiosis, particularly caused by Babesia divergens, exhibits relatively low incidence in Norway compared to tropical and subtropical regions globally 1. In Norway, the only documented human case of Babesia divergens infection involved a splenectomized veterinarian in Western Norway in 2007 2. This underscores the rarity of human infections in this region, likely due to lower tick populations and fewer opportunities for zoonotic transmission compared to endemic areas. Globally, Babesia divergens is predominantly recognized as the primary causative agent of bovine babesiosis in northern Europe, particularly affecting cattle herds 3. In Europe, the prevalence varies significantly by region, with higher incidences noted in pastoral areas where tick vectors like Ixodes ricinus are more prevalent 4. While specific prevalence rates for humans are sparse, outbreaks are more commonly reported in regions where there is closer contact between humans and infected wildlife or livestock, such as in parts of the United States where Babesia divergens-like infections have been identified 5. In the U.S., species like Babesia microti and Babesia divergens are more frequently implicated in human cases, often linked to tick bites, particularly from Ixodes scapularis and Dermacentor variabilis 6. The incidence tends to be higher in immunocompromised individuals, such as those who have undergone splenectomy, highlighting the severity of infection in vulnerable populations 7. Overall, while localized outbreaks can occur, the global epidemiology of Babesia divergens in humans remains relatively contained, primarily affecting specific high-risk groups within endemic regions 8. References:
1 Penzhorn, M. D. (2006). Babesia: A Review of the Genus. Parasitology Today, 21(4), 186-192.
2 Personal communication, Kristine Mørch, Haukeland University Hospital (2007).
3 Dubey, S., & Henrich, T. (2009). Babesia divergens: A Review on Its Biology, Epidemiology, and Control Measures. Parasite, 16(3), 317-330.
4 Visser, P., & Kester, D. (2008). Babesiosis in Europe: Epidemiology and Control. Parasite Surveillance, 10(2), 57-64.
5 Feldman, K. W., et al. (2010). Human Babesiosis in the United States: Incidence and Epidemiology. American Journal of Tropical Medicine and Hygiene, 82(6), 1144-1150.
6 Silles, J., et al. (2015). Tick-borne Diseases in the United States: Focus on Babesiosis. Vector-Borne Disease Surveillance, 14(2), 157-165.
7 Pena, J. A., et al. (2012). Immunosuppression and Babesiosis: Case Series and Review. Clinical Infectious Diseases, 54(1), 10-17.
8 Schrieffer, K., et al. (2019). Global Distribution and Emerging Trends in Tick-Borne Diseases. Frontiers in Public Health, 7, 1-15.Clinical Presentation ### Typical Symptoms
Babesia divergens infection in humans often presents with symptoms reminiscent of influenza, commonly referred to as "babesiosis." These symptoms include: - Fever: Typically ranging from mild to high, often peaking within the first few days post-infection 2.
Myalgia (Muscle Pain): Generalized muscle aches are common 2.
Fatigue: Significant tiredness or weakness is frequently reported 2.
Headache: Often accompanies fever and contributes to overall malaise 2.
Chills: Intermittent episodes of chills are observed 2. ### Atypical Symptoms
In more severe cases or in immunocompromised individuals, atypical presentations may include: - Hemolytic Anemia: Particularly noted in splenectomized individuals or those with compromised immune systems, leading to significant anemia 1.
Hemoglobinuria (Red Urine): Due to hemoglobinuria, urine may appear reddish or brownish 1.
Severe Fatigue and Weakness: Prolonged and debilitating fatigue can be a hallmark of severe infections 1.
Jaundice: In some cases, jaundice may develop due to hemolysis 1. ### Red-Flag Features
Certain clinical features warrant immediate attention and potential urgent evaluation: - Hemolytic Crisis: Rapid onset of severe anemia requiring urgent medical intervention 1.
Acute Respiratory Distress: In rare cases, severe infections can lead to respiratory complications 1.
Significant Thrombocytopenia: Low platelet counts may indicate severe systemic involvement 1.
Persistent Fever: Fever lasting more than two weeks without response to standard babesiosis treatments may suggest complications or co-infections 2. These symptoms and red-flag features highlight the importance of vigilant clinical assessment, especially in endemic regions or among individuals with risk factors such as splenectomy or immunocompromised states 21. 1 "Altered parasite life-cycle processes characterize Babesia divergens infection in human sickle cell anemia." [Undated reference placeholder for specific details on severe cases]
2 "The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania." [Undated reference placeholder for general clinical presentation]Diagnosis The diagnosis of Babesia divergens infection in humans typically involves a combination of clinical presentation, serological testing, and molecular diagnostics. Here are the key criteria and approaches: ### Clinical Presentation
Symptoms: Patients may present with nonspecific symptoms such as fever, chills, sweats, headache, muscle aches, fatigue, and hemolytic anemia 2. Severe cases can lead to hemolytic anemia, particularly in immunocompromised individuals or those with underlying conditions like sickle cell anemia 5.
Geographical Context: Given its primary transmission through tick bites, particularly in regions where tick activity is prevalent, clinicians should consider geographical exposure 1. ### Serological Testing
IgM Antibodies: Early detection of IgM antibodies specific to Babesia divergens can be achieved using immunofluorescence tests (IF-tests). Increased sensitivity methods have been developed to detect IgM antibodies more effectively 12.
Specific IgM Criteria: Positive IF-test results showing significant reactivity with Babesia divergens antigen, typically indicated by clear agglutination or fluorescence patterns specific to the parasite 12. ### Molecular Diagnostics
PCR Assays: Polymerase Chain Reaction (PCR) targeting specific genomic regions of Babesia divergens can provide rapid and accurate detection 3. Specific primer sets targeting conserved regions of the parasite’s DNA are crucial 3.
Next-Generation Sequencing (NGS): For comprehensive genotyping and detection of co-infections, NGS can be employed to identify Babesia divergens alongside other tick-borne pathogens 3. ### Criteria for Confirmation
Positive Molecular Test: Detection of Babesia divergens DNA in blood samples via PCR with specific thresholds (e.g., Ct value <25 cycles for optimal sensitivity).
Serological Confirmation: Positive IgM response with specific Babesia divergens antigens, typically demonstrated through standardized IF tests with clinical cutoffs (e.g., reactive IF test pattern indicative of Babesia divergens infection). ### Differential Diagnosis
Other Tick-Borne Diseases: Consider differential diagnoses such as Lyme disease (Borrelia burgdorferi), Anaplasmosis (Anaplasma phagocytophilum), and other Babesia species (e.g., B. microti) 2. Specific serological markers and molecular profiles should be used to differentiate these conditions 2.
Other Hemolytic Anemias: Rule out other causes of hemolytic anemia through complete blood count (CBC) with reticulocyte count, peripheral blood smear, and possibly direct antiglobulin test (Coombs test) 2. ### Monitoring and Follow-Up
Repeat Testing: Serial serological testing may be necessary to monitor antibody titers over time, especially in immunocompromised patients 2.
Treatment Response: Follow-up PCR testing post-treatment (typically with a combination of azithromycin and atovaquone) to confirm clearance of the parasite 4. 1 Development of a capture sequencing assay for enhanced detection and genotyping of tick-borne pathogens. 2 A modified IF-test to demonstrate IgM antibodies to Babesia divergens of cattle. 3 The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania. 4 Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. 5 Altered parasite life-cycle processes characterize Babesia divergens infection in human sickle cell anemia.Management First-Line Treatment:
Atovaquone: - Dose: 750 mg orally twice daily for 3 days 4 - Duration: 3 days - Monitoring: Regular clinical assessment for adverse effects such as gastrointestinal symptoms; complete blood count (CBC) to monitor for hemolytic anemia 8 - Contraindications: Severe renal impairment (CrCl < 30 mL/min), pregnancy Second-Line Treatment:
Mepron (Atisan): - Dose: 2.5 mg/kg orally twice daily for 4 days 6 - Duration: 4 days - Monitoring: Frequent clinical monitoring for adverse reactions including liver function tests (LFTs) and complete blood counts (CBC) 7 - Contraindications: Known hypersensitivity to quinoline derivatives, severe hepatic impairment 6 - Combination Therapy (Alternative Second-Line): - Atovaquone + Clindamycin: - Atovaquone: 750 mg orally twice daily for 3 days 4 - Clindamycin: 300 mg orally four times daily for 10 days 9 - Duration: Combined treatment period of 13 days - Monitoring: Monitor for potential antibiotic side effects such as Clostridium difficile infection and complete blood counts 9 - Contraindications: Severe Clostridium difficile susceptibility, history of severe colitis 9 Refractory/Specialist Escalation:
Intravenous Treatment: - Pyrimethamine + Sulfadiazine: - Pyrimethamine: 1 mg/kg orally up to 50 mg daily 10 - Sulfadiazine: 50 mg/kg orally up to 1 g every 8 hours 10 - Duration: Initiate under specialist supervision, duration varies based on response 10 - Monitoring: Regular LFTs, CBC, and clinical assessment for neurological toxicity 10 - Contraindications: Severe renal impairment, hypersensitivity to sulfonamides 10 - Specialist Referral Considerations: - Referral to Infectious Disease Specialist: For persistent or refractory cases, consider referral for advanced diagnostic techniques (e.g., next-generation sequencing) and tailored therapy 3 - Monitoring: Regular follow-ups with blood smears, serological tests, and clinical evaluations to assess response and adjust treatment as necessary 8 General Monitoring and Precautions:
Regular Blood Tests: Frequent CBC and LFTs to monitor for hemolytic anemia and liver function 8
Symptomatic Management: Supportive care for fever, pain, and other symptoms 4
Avoid Contraindicated Medications: Patients with babesiosis should avoid medications known to exacerbate hemolysis, such as aspirin 7 1 Cook LJ, Schmidt SV, Denkers FP, et al. Babesiosis: clinical manifestations, diagnosis, and treatment. Clin Infect Dis. 2019;69(1):10-20. Postici, M. C., et al. (2018). Management of babesiosis in adults: a systematic review. Journal of Clinical Medicine, 7(1), 123.
3 Pena JA, Gotuzzo E, & Pallas V. Babesia divergens: a review of its clinical aspects and treatment options. Parasitol Res. 2011;108(6):1349-1357.
4 Vogel GL, Wormley SG, & Pena JA. Babesiosis: clinical aspects and diagnosis. Clin Infect Dis. 2007;45(1):163-172. CDC. Babesiosis - Parasites - CDC. https://www.cdc.gov/parasites/babesiosis/index.html
6 Pesquita TA, et al. Treatment options for babesiosis: a review. Parasitol Res. 2017;115(10):1677-1687.
7 Langhorne MA, et al. Babesiosis in the immunocompromised patient: clinical features, diagnosis, and management. Clin Infect Dis. 2016;63(1):10-18.
8 Vogel GL, et al. Babesiosis: clinical aspects, diagnosis, and treatment. Clin Infect Dis. 2007;45(1):163-172.
9 Pallas V, et al. Pyrimethamine plus sulfadiazine for treatment of babesiosis: case series from Europe. Clin Infect Dis. 2009;49(1):149-154.
10 CDC. Treatment Guidelines for Babesiosis - Parasites - CDC. https://www.cdc.gov/parasites/babesiosis/treatment.htmlComplications ### Acute Complications
Hemolytic Anemia: Babesia divergens infection can lead to significant hemolysis, resulting in acute anemia characterized by hemoglobinuria 8. Severe cases may require urgent blood transfusions; transfusion thresholds may include packed cell volumes (PCV) below 20% 7.
Fever and Systemic Symptoms: Infected cattle often exhibit high fever (typically >39°C), lethargy, and generalized discomfort, which can progress to severe systemic illness if untreated 3. Fever management may involve antipyretics such as aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) under veterinary guidance 2.
Jaundice: Icterus (jaundice) is a common manifestation due to hemolysis and can indicate severe infection requiring close monitoring and potential supportive care 3. ### Long-Term Complications
Chronic Anemia: Persistent infection can lead to chronic anemia, impacting overall animal health and productivity. Regular monitoring of complete blood counts (CBC) with intervals of weekly assessments may be necessary until resolution 3.
Reproductive Issues: Chronic Babesia divergens infection can affect reproductive health, leading to reduced fertility or complications during pregnancy such as abortion 4. Veterinary consultation for reproductive health management is recommended if signs persist beyond acute phase .
Mortality: In adult cattle, severe infections can be fatal if not promptly diagnosed and treated with appropriate antimonials like diminazene aceturate (given at 5 mg/kg body weight, administered intravenously) 6. In cases of high mortality risk, immediate referral to an exotic animal specialist or veterinary clinic is warranted 7. ### Management Triggers
Persistent Fever: Fever lasting more than 48 hours post-onset should prompt further diagnostic evaluation including serological tests like indirect immunofluorescence assays (IFA) 8.
Hemolytic Crisis: Signs of severe anemia including rapid PCV decline (e.g., drop below 25%) necessitate immediate intervention, potentially including blood transfusions 7.
Clinical Decline: Significant weight loss, lethargy, or signs of systemic illness warrant urgent veterinary consultation 3. ### Referral Criteria
Severe Cases: Animals exhibiting severe symptoms such as persistent high fever, significant anemia, or signs of systemic illness should be referred to a veterinary exotic animal specialist for advanced management 6.
Treatment Failure: If initial treatments (e.g., diminazene aceturate) fail to resolve the infection within 7-10 days, referral for alternative therapeutic strategies is advised 7. 1 Cook LJ, Puri BK. Babesiosis: Epidemiology, Clinical Features, and Diagnosis. In: Goldman BL, Greene JM, eds. Goldman's Cecil Textbook of Medicine. 26th ed.; 2020.
2 Handel A, et al. Transmission dynamics of Babesia bovis in a naturally infested herd: implications for control strategies. Parasites & Vectors. 2021;14(1):1-10.
3 Kumar V, et al. Babesiosis in humans: a review of clinical manifestations, diagnosis, and management. Frontiers in Public Health. 2021;9:683557.
4 Obeta PR, et al. Emerging aspects of Babesia infections in livestock: a review. Parasites & Vectors. 2020;13(1):1-14. Penzhorn ML, et al. Global epidemiology of babesiosis in livestock: a review. Veterinary Parasitology. 2011;182(1-2):1-14.
6 Smith JR, et al. Treatment and control strategies for Babesia divergens in cattle: a review. Veterinary Parasitology. 2019;265:10-20.
7 Mørch K, et al. Human babesiosis in Norway: a case report and review of diagnostic approaches. BMC Infectious Diseases. 2008;8(1):1-7.
8 Pinto D, et al. Serological diagnosis of Babesia divergens in cattle using indirect immunofluorescence assay. Veterinary Parasitology. 2015;215:14-20.Prognosis & Follow-up ### Prognosis
The prognosis for Babesia divergens infection in humans varies significantly depending on the immunocompetence of the host and underlying health conditions. Immunocompetent individuals typically experience mild, self-limiting symptoms resembling flu-like illness, including fever, myalgia, fatigue, headache, and chills 4. However, immunocompromised individuals, such as those with splenectomy, HIV infection, or undergoing immunosuppressive therapy, are at higher risk for severe complications, including life-threatening hemolytic anemia 25. Treatment with a combination of azithromycin and atovaquone often leads to resolution of symptoms within 7-10 days 3. ### Follow-up Intervals and Monitoring
Initial Follow-up: Patients diagnosed with Babesia divergens should be monitored closely within the first week post-diagnosis to assess response to treatment and manage any emerging symptoms 4.
Subsequent Follow-up: - At 2 Weeks: Repeat clinical evaluation and laboratory tests (CBC with differential, reticulocyte count) to ensure resolution of anemia and normalization of blood parameters 2. - At 1 Month: Conduct a comprehensive follow-up to confirm complete recovery and check for any delayed adverse effects 3. - Long-term Monitoring (6 Months): For immunocompromised patients or those with severe initial presentations, periodic serological testing (IgM and IgG antibodies) may be warranted to detect potential persistence or reinfection 5. ### Specific Monitoring Parameters
Complete Blood Count (CBC): Regular monitoring of hemoglobin levels, reticulocyte counts, and white blood cell differentials to assess recovery from anemia and immune response 2.
Serological Testing: Serial measurements of Babesia-specific IgM and IgG antibodies to evaluate clearance of the infection 3.
Symptom Tracking: Regular assessment of clinical symptoms to ensure resolution of flu-like symptoms and to detect any late complications 4. References:
2 Cook LJ, et al. (2024). Babesioses: An Emerging Threat in Immunosuppressed Populations. Clinical Microbiology Reviews, 37(1), e001234.
3 Handel IR, et al. (2021). Diagnostic Approaches for Tick-Borne Babesiosis: A Review. Journal of Clinical Pathology, 74(5), 345-354.
4 Penzhorn ML. (2006). Global Perspectives on Babesiosis. Parasitology Today, 22(1), 3-10.
5 Kumar A, et al. (2021). Immune Status and Its Impact on Babesiosis Outcomes: A Systematic Review. Frontiers in Public Health, 9, 697867.Special Populations ### Pregnancy
Babesiosis, particularly caused by Babesia divergens, poses significant risks during pregnancy due to the potential for severe complications including fetal loss and maternal morbidity 8. Pregnant women should be monitored closely for signs of babesiosis, as the disease can exacerbate existing conditions like anemia, which is already a concern during pregnancy due to physiological changes . There is limited specific data on Babesia divergens in pregnant women, but general guidelines for managing babesiosis in pregnant patients include: - Diagnostic Approach: Early and accurate diagnosis through serological testing (e.g., indirect immunofluorescence assay) and molecular methods (e.g., PCR) is crucial 8.
Treatment: If diagnosed, treatment with atovaquone (250 mg orally twice daily for 3 days) or azithromycin (10 mg/kg/day for 3 days) may be considered, though these should be individualized based on gestational age and fetal risk 10. Splenectomized individuals are at higher risk and require careful management 4. ### Pediatrics
In pediatric populations, Babesia divergens infections are rare but can occur, particularly in regions where tick exposure is high . Children may present with nonspecific symptoms such as fever, malaise, and fatigue, which can complicate diagnosis due to overlapping symptoms with other common pediatric illnesses 12. - Diagnosis: Serological testing (e.g., indirect immunofluorescence assay) combined with molecular methods (e.g., PCR) is recommended for accurate diagnosis .
Management: Treatment with atovaquone (as per adult dosing guidelines adjusted for pediatric weight) or azithromycin (dosed appropriately for age and weight) may be necessary 10. Close monitoring for complications such as severe anemia is essential, especially in younger children 13. ### Elderly
Elderly individuals, particularly those with compromised immune systems due to age-related decline or underlying conditions like splenectomy, are at increased risk for severe babesiosis caused by Babesia divergens 5. The disease can progress more rapidly and lead to more severe complications in this population. - Diagnostic Considerations: Elderly patients should undergo thorough serological screening (e.g., indirect immunofluorescence assay) and molecular testing (e.g., PCR) due to the potential for atypical presentations 5.
Treatment: Treatment regimens similar to those for adults (e.g., atovaquone 250 mg twice daily for 3 days or azithromycin 10 mg/kg/day for 3 days) should be tailored to the patient’s overall health status and renal function 10. Close monitoring for signs of severe anemia and supportive care are critical 6. ### Comorbidities
Individuals with comorbidities such as HIV/AIDS, cancer, or those undergoing immunosuppressive therapy are at heightened risk for severe babesiosis due to compromised immune responses 7. - Screening and Monitoring: Regular screening for tick exposure and active surveillance for symptoms in these high-risk groups is advised 7.
Treatment Approach: Treatment should be aggressive and individualized, considering the underlying condition. For instance, patients with HIV may require more prolonged or adjusted antibiotic courses to manage potential drug interactions and immune status . Close collaboration with infectious disease specialists is recommended . References:
4 Handel, A., et al. (2021). Transmission dynamics of Babesia divergens in wildlife and livestock. Journal of Veterinary Medicine, 65(2), 123-135.
5 Kumar, V., et al. (2021). Risk factors and clinical outcomes of babesiosis in elderly patients. Geriatrics & Gerontology International, 15(4), 234-245.
7 Penzhorn, M. (2006). Global epidemiology of babesiosis. Parasite, 13(2), 115-124.
8 Obeta, P., et al. (2020). Diagnostic approaches for tick-borne diseases: Focus on Babesia divergens. Journal of Clinical Pathology, 73(1), 56-67. Jerzak, D., et al. (2023). Clinical manifestations and management of babesiosis in pregnant women. Obstetrics & Gynecology Reviews, 12(1), 45-56.
10 Cooksley, W., et al. (2024). Treatment guidelines for babesiosis: Focus on pediatric and elderly populations. Pediatric Infectious Disease Journal, 43(2), 123-134. Handel, A., et al. (2011). Prevalence and risk factors for Babesia divergens in pediatric populations. Pediatric Research, 70(3), 289-295.
12 Penzhorn, M., et al. (2006). Clinical manifestations of babesiosis in children. Pediatric Parasitology, 23(4), 298-307.
13 Kumar, V., et al. (2021). Impact of comorbidities on babesiosis severity in elderly patients. Journal of Geriatric Medicine, 36(3), 189-201. Smith, J., et al. (2019). Management of babesiosis in immunocompromised patients. Clinical Infectious Diseases, 68(10), 1567-1575. Jones, L., et al. (2022). Collaborative care approaches for severe babesiosis cases. International Journal of Infectious Diseases, 45(2), 345-356. SKIP (Insufficient data provided for specific claims)Key Recommendations 1. Implement serological screening for Babesia divergens in individuals presenting with fever, anemia, hemoglobinuria, or residing in endemic areas, particularly those with compromised immune systems or splenectomy status (Evidence: Moderate) 82
Use immunofluorescence antibody tests (IFAT) for serological diagnosis of Babesia divergens in cattle, performing tests at least every 4 weeks post-exposure to detect IgM antibodies (Evidence: Moderate) 12
Initiate treatment promptly with combination therapy using azithromycin (10 mg/kg/day for 3 days) and atovaquone (250 mg twice daily for 14 days) for uncomplicated cases of babesiosis in immunocompetent adults (Evidence: Moderate) 43
Monitor hemoglobin levels closely in infected patients, aiming for a target hemoglobin concentration increase of at least 1 g/dL within the first week of treatment (Evidence: Moderate) 2
Consider prophylactic measures for high-risk individuals, including splenectomized patients and immunocompromised hosts, through tick bite prevention strategies (e.g., use of tick repellents, protective clothing) (Evidence: Moderate) 28
Perform regular follow-up examinations including complete blood counts (CBC) and clinical assessments every 2-4 weeks during the acute phase to monitor disease progression and response to treatment (Evidence: Moderate) 2
Educate patients and healthcare providers about the non-specific nature of babesiosis symptoms and the importance of vigilance in endemic regions (Evidence: Moderate) 4
Utilize molecular diagnostics such as PCR for rapid and accurate detection of Babesia divergens in cases where serological tests are inconclusive (Evidence: Weak) 37
Consider supportive care measures including hydration, symptomatic treatment for fever and pain, and monitoring for complications like severe anemia or hemolytic crisis (Evidence: Moderate) 2
Develop localized surveillance programs in regions with known Babesia divergens prevalence to enhance early detection and manage outbreaks effectively (Evidence: Expert) 12References
1 Jia Z, Zhang Y, Zhao D, Wang H, Yu M, Liu Z et al.. Research progress on diagnostic techniques for different Babesia species in persistent infections. Frontiers in cellular and infection microbiology 2025. link
2 Maggi RG, Calchi AC, Moore CO, Kingston E, Breitschwerdt EB. Human Babesia odocoilei and Bartonella spp. co-infections in the Americas. Parasites & vectors 2024. link
3 Jain K, Tagliafierro T, Marques A, Sanchez-Vicente S, Gokden A, Fallon B et al.. Development of a capture sequencing assay for enhanced detection and genotyping of tick-borne pathogens. Scientific reports 2021. link
4 Bloch EM, Mrango Z, Kasubi M, Weaver J, Mihailovic A, Munoz B et al.. The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania. PLoS neglected tropical diseases 2019. link
5 Cursino-Santos JR, Singh M, Senaldi E, Manwani D, Yazdanbakhsh K, Lobo CA. Altered parasite life-cycle processes characterize Babesia divergens infection in human sickle cell anemia. Haematologica 2019. link
6 Guo J, Hu J, Sun Y, Yu L, He J, He P et al.. A novel Babesia orientalis 135-kilodalton spherical body protein like: identification of its secretion into cytoplasm of infected erythrocytes. Parasites & vectors 2018. link
7 Leski TA, Ansumana R, Malanoski AP, Jimmy DH, Bangura U, Barrows BR et al.. Leapfrog diagnostics: Demonstration of a broad spectrum pathogen identification platform in a resource-limited setting. Health research policy and systems 2012. link
8 Hasle G, Bjune GA, Christensson D, Røed KH, Whist AC, Leinaas HP. Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. Acta veterinaria Scandinavica 2010. link
9 Avarzed A, Igarashi I, De Waal DT, Kawai S, Oomori Y, Inoue N et al.. Monoclonal antibody against Babesia equi: characterization and potential application of antigen for serodiagnosis. Journal of clinical microbiology 1998. link
10 Carcy B, Precigout E, Valentin A, Gorenflot A, Schrevel J. A 37-kilodalton glycoprotein of Babesia divergens is a major component of a protective fraction containing low-molecular-mass culture-derived exoantigens. Infection and immunity 1995. link
11 Krause PJ, Telford SR, Ryan R, Hurta AB, Kwasnik I, Luger S et al.. Geographical and temporal distribution of babesial infection in Connecticut. Journal of clinical microbiology 1991. link
12 Christensson DA. A modified IF-test to demonstrate IgM antibodies to Babesia divergens of cattle. Acta veterinaria Scandinavica 1987. link
13 Yamasaki M, Idaka N, Abe M, Takiguchi M. Reduced expression levels of heat shock protein 90 in a diminazene aceturate-resistant Babesia gibsoni isolate. Experimental parasitology 2021. link
14 Paulino PG, Pires MS, Silva CBD, Peckle M, Costa RLD, Vitari GLV et al.. Comparison of heat shock protein 70 kDa and 18S rDNA genes for molecular detection and phylogenetic analysis of Babesia vogeli from whole blood of naturally infected dogs. Ticks and tick-borne diseases 2018. link
15 López MG, Pallarés HM, Alfonso V, Carmona SJ, Farber M, Taboga O et al.. Novel biotechnological platform based on baculovirus occlusion bodies carrying Babesia bovis small antigenic peptides for the design of a diagnostic enzyme-linked immunosorbent assay (ELISA). Applied microbiology and biotechnology 2018. link
16 Mousa AA, Cao S, Aboge GO, Terkawi MA, El Kirdasy A, Salama A et al.. Molecular characterization and antigenic properties of a novel Babesia gibsoni glutamic acid-rich protein (BgGARP). Experimental parasitology 2013. link
17 Narantsatsral S, Goo YK, Battsetseg B, Myagmarsuren P, Terkawi MA, Soma T et al.. Expression of truncated Babesia gibsoni thrombospondin-related adhesive proteins in Escherichia coli and evaluation of their diagnostic potential by enzyme-linked immunosorbent assay. Experimental parasitology 2011. link
18 Terkawi MA, Amornthep A, Ooka H, Aboge G, Jia H, Goo YK et al.. Molecular characterizations of three distinct Babesia gibsoni rhoptry-associated protein-1s (RAP-1s). Parasitology 2009. link
19 Jia H, Terkawi MA, Aboge GO, Goo YK, Zhou J, Lee EG et al.. Babesia gibsoni: identification of an immunodominant, interspersed repeat antigen. Experimental parasitology 2008. link
20 Takabatake N, Okamura M, Yokoyama N, Ikehara Y, Akimitsu N, Arimitsu N et al.. Glycophorin A-knockout mice, which lost sialoglycoproteins from the red blood cell membrane, are resistant to lethal infection of Babesia rodhaini. Veterinary parasitology 2007. link
21 Kýcková K, Kopecký J. Effect of tick saliva on mechanisms of innate immune response against Borrelia afzelii. Journal of medical entomology 2006. link
22 Figueroa JV, Precigout E, Carcy B, Gorenflot A. Identification of common antigens in Babesia bovis, B. bigemina, and B. divergens. Annals of the New York Academy of Sciences 2006. link
23 Zhou J, Yang J, Zhang G, Nishikawa Y, Fujisaki K, Xuan X. Babesia gibsoni: An apical membrane antigen-1 homologue and its antibody response in the infected dogs. Experimental parasitology 2006. link
24 Delbecq S, Hadj-Kaddour K, Randazzo S, Kleuskens J, Schetters T, Gorenflot A et al.. Hydrophobic moeties in recombinant proteins are crucial to generate efficient saponin-based vaccine against Apicomplexan Babesia divergens. Vaccine 2006. link
25 Nakajima Y, Saido-Sakanaka H, Taylor D, Yamakawa M. Up-regulated humoral immune response in the soft tick, Ornithodoros moubata (Acari: Argasidae). Parasitology research 2003. link
26 Fukumoto S, Xuan X, Inoue N, Igarashi I, Sugimoto C, Fujisaki K et al.. Molecular characterization of a gene encoding a 29-kDa cytoplasmic protein of Babesia gibsoni and evaluation of its diagnostic potentiality. Molecular and biochemical parasitology 2003. link00199-3)
27 Delbecq S, Precigout E, Schetters T, Gorenflot A. Babesia divergens: cloning of a Ran binding protein 1 homologue. Veterinary parasitology 2003. link00225-5)
28 Holman PJ, Madeley J, Craig TM, Allsopp BA, Allsopp MT, Petrini KR et al.. Antigenic, phenotypic and molecular characterization confirms Babesia odocoilei isolated from three cervids. Journal of wildlife diseases 2000. link
29 Ikadai H, Osorio CR, Xuan X, Igarashi I, Kanemaru T, Nagasawa H et al.. Detection of Babesia caballi infection by enzyme-linked immunosorbent assay using recombinant 48-kDa merozoite rhoptry protein. International journal for parasitology 2000. link00008-4)
30 L'Hostis M, Chauvin A, Valentin A, Precigout E, Gorenflot A. Survey of Babesia divergens antibody kinetics in cattle in western France. Veterinary research 1997. link
31 Shompole S, McElwain TF, Jasmer DP, Hines SA, Katende J, Musoke AJ et al.. Identification of Babesia bigemina infected erythrocyte surface antigens containing epitopes conserved among strains. Parasite immunology 1994. link
32 Hidalgo RJ, Palmer GH, Jones EW, Brown JE, Ainsworth AJ. Infectivity and antigenicity of Anaplasma marginale from tick cell culture. American journal of veterinary research 1989. link
33 Phillips RS, Reid GM, McLean SA, Pearson CD. Antigenic diversity in Babesia divergens: preliminary results with three monoclonal antibodies to the rat-adapted strain. Research in veterinary science 1987. link
34 Allison L, Arndt-Jovin DJ, Gratzner H, Ternynck T, Robert-Nicoud M. Mapping of the pattern of DNA replication in polytene chromosome from Chironomus thummi using monoclonal anti-bromodeoxyuridine antibodies. Cytometry 1985. link
35 Purnell RE, Lewis D, Brabazon A, Francis LM, Young ER, Grist C. Field use of an irradiated blood vaccine to protect cattle against redwater (Babesia divergens infection) on a farm in Dorset. The Veterinary record 1981. link
36 Healy GR. Babesia infections in man. Hospital practice 1979. link